Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > REGULATORY
REGULATORY
- MEXT’s FY2018 Budget Request to Include Funding to Build Biobank Network
September 8, 2017
- MHLW Sets Out Plan to Ease Export Ban for Plasma Fraction Products
September 7, 2017
- MHLW Working Group to Draw Up Elderly Polypharmacy Guidelines in 2 Stages
September 4, 2017
- Spinraza Add’l Indication Reported to MHLW Panel, Setting Stage for Its Use in All SMA Patients
September 4, 2017
- Programs Funded by MA Holder or Its Subsidiaries Subject to Regulations under Clinical Research Law
September 1, 2017
- MHLW to Form Study Group to Address Leftover Vial Drug Issue, Weighs Multi-Dose Vials
August 30, 2017
- MHLW Panels Eye Cognitive Behavioral Therapy Approach for Post-HPV Vaccine Symptoms
August 29, 2017
- New Minister Has Hopes for Pharma Industry in Both Medical and Economic Fronts, Wants to Balance Innovation and Cost
August 29, 2017
- MHLW Predicts 4% Reduction in Flu Vaccine Production in FY2017, Will Take Steps to Prevent Shortage
August 29, 2017
- MHLW OKs Add’l Indications for Revolade, Actemra and More
August 28, 2017
- Opdivo’s Gastric Cancer Use, Avelumab and More Up for MHLW Panel Review/Report on Sept. 8
August 28, 2017
- MHLW Health Policy Bureau to Initiate a New Project to Increase Understanding of Biosimilars; FY2018 Budget Request
August 28, 2017
- MHLW Pharmaceutical Safety Bureau Seeks 10.3 Billion Yen in FY2018 Budget; Includes Funding for 6 Add’l Personnel at PMDA
August 28, 2017
- MHLW Working Group to Kick Off Discussions on Guidelines to Address Elderly Polypharmacy
August 25, 2017
- MHLW Seeks 31.4 Trillion Yen in FY2018 Budget, 630 Billion Yen in Natural Rise for Social Security
August 25, 2017
- MHLW Council Recommends Public Knowledge-Based Applications for 2 Products Including Velcade
August 25, 2017
- MHLW Presents Steps Responding to Chuikyo Reps’ Concerns for “Willing-to-Pay Cost” Survey
August 24, 2017
- Chuikyo OKs MHLW’s Discussion Timeline on CEA, 3 Subcommittees to Hold Joint Debates
August 24, 2017
- Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too
August 24, 2017
- Leftover Spinraza in 9-Million-Yen Vial Must Be Discarded, Can’t Be Saved for Next Time: MHLW Official
August 23, 2017
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…